Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Gedye

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Frontiers in Genetics|November 7, 2013
A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cellsRamakrishna Sompallae, Oliver Hofmann, Christopher A Maher, et al.
Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.
Oncoimmunology|June 5, 2013
Human perforin mutations and susceptibility to multiple primary cancersJoseph A Trapani, Kevin Y T Thia, Miles Andrews, et al.
Scientific Reports|April 29, 2016
Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinomaCraig Gedye, Danylo Sirskyj, Nazleen C Lobo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.
BMC Cancer|July 17, 2016
Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicineNazleen C Lobo, Craig Gedye, Anthony J Apostoli, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
BMC Cancer|December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Swetha Sridharan, James Lynam, et al.
Cell|May 6, 2017
An Immune Atlas of Clear Cell Renal Cell CarcinomaStéphane Chevrier, Jacob Harrison Levine, Vito Riccardo Tomaso Zanotelli, et al.
Neuro-Oncology Advances|May 31, 2021
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastomaMustafa Khasraw, Michael Weller, David Lorente, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Frontiers in Genetics|November 7, 2013
A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cellsRamakrishna Sompallae, Oliver Hofmann, Christopher A Maher, et al.
Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.
Oncoimmunology|June 5, 2013
Human perforin mutations and susceptibility to multiple primary cancersJoseph A Trapani, Kevin Y T Thia, Miles Andrews, et al.
Scientific Reports|April 29, 2016
Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinomaCraig Gedye, Danylo Sirskyj, Nazleen C Lobo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.
BMC Cancer|July 17, 2016
Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicineNazleen C Lobo, Craig Gedye, Anthony J Apostoli, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
BMC Cancer|December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Swetha Sridharan, James Lynam, et al.
Cell|May 6, 2017
An Immune Atlas of Clear Cell Renal Cell CarcinomaStéphane Chevrier, Jacob Harrison Levine, Vito Riccardo Tomaso Zanotelli, et al.
Neuro-Oncology Advances|May 31, 2021
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastomaMustafa Khasraw, Michael Weller, David Lorente, et al.
Pageof 8